Treatment of Pneumocystis jirovecii Pneumonia with Caspofungin and Clindamycin: An HIV Patient and Literature Review
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Bilimsel Tip Yayinevi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
The first-line treatment for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim-sulfamethoxazole (TMP-SMZ). However, some cases require alternative agents due to the side effects of TMP-SMZ. Treatment with TMP-SMZ was initiated in an HIV-positive patient with microbiologically confirmed PCP, who presented with acute renal failure on admission. On the third day of treatment, TMP-SMZ was discontinued due to worsening renal function. Subsequently, clindamycin was initiated in combination with caspofungin. Although caspofungin-based therapies were shown to be effective against Pneumocystis in animal models, clinical experience in humans is limited. The patient was treated successfully with clindamycin combined with caspofungin.
Açıklama
Anahtar Kelimeler
Words, Pneumocystis jirovecii, Clindamycin, Caspofungin
Kaynak
Flora Infeksiyon Hastaliklari Ve Klinik Mikrobiyoloji Dergisi
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
29
Sayı
1
